Granules India, a leading generic drug manufacturer, is venturing into the peptide segment and contract development and manufacturing organization (CDMO) business through its acquisition of Swiss-based Senn Chemicals AG. This acquisition, expected to close in the first half of 2025, will enhance Granules’ capabilities in peptide synthesis and contract-based research, development, and manufacturing.

Senn specializes in liquid-phase (LPPS) and solid-phase peptide synthesis (SPPS), serving global clients in the pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic industries. The company’s manufacturing facility is ISO 9001:2015 certified and approved for cGMP production by Swissmedic, whose inspections are recognized by the US FDA under a mutual recognition agreement.

Granules and Senn have been collaborating on the development of two GLP-1-based active pharmaceutical ingredients (APIs), with plans to expand their peptide-based API portfolio using Senn’s research expertise. This acquisition strengthens Granules’ presence in Europe, providing access to a skilled R&D talent pool and a well-regulated market.

By integrating Senn’s specialized capabilities with its large-scale, cost-efficient manufacturing, Granules aims to become a key player in peptide-based therapeutics, spanning pharmaceuticals, cosmetics, and theragnostic applications. This move aligns with Granules’ vision of science-driven innovation and expansion into next-generation therapeutics, solidifying its position as a trusted partner in complex drug development.